智通财经APP讯,迪哲医药(688192.SH)发布公告,公司将于12月6日至9日在第67届美国临床血液学会(American Society of Hematology,ASH)大会上,公布淋巴瘤治疗领域两大核心产品高瑞哲®(通用名:戈利昔替尼胶囊)和birelentinib(DZD8586)多项最新研究成果。本次大会,公司共有15篇摘要入选,充分展现了公司在血液肿瘤治疗领域的丰富管线组合以及研发潜力。
智通财经APP讯,迪哲医药(688192.SH)发布公告,公司将于12月6日至9日在第67届美国临床血液学会(American Society of Hematology,ASH)大会上,公布淋巴瘤治疗领域两大核心产品高瑞哲®(通用名:戈利昔替尼胶囊)和birelentinib(DZD8586)多项最新研究成果。本次大会,公司共有15篇摘要入选,充分展现了公司在血液肿瘤治疗领域的丰富管线组合以及研发潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.